Pfizer Full Year 2025 Financial ReportPfizerPfizer’s 2025 financial results show a 2% decline in revenue, driven by lower COVID-19 product sales. Non-COVID products and a strong R&D pipeline drive growth. The company projects steady performance with key catalysts in 2026.
Global Biopharma Layoffs December 2025LayoffsThis article tracks recent biotech and pharma layoffs, including major workforce cuts at Voyager Therapeutics, Intercept Pharmaceuticals, Mythic Therapeutics, Pfizer, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
Global Biopharma Layoffs August 2025LayoffsThe biopharmaceutical industry sees major August layoffs, with companies like Moderna, Merck cutting jobs amid restructurings, trial setbacks, and M&A activity.
Pfizer 2025 H1 ReportFinancial statementsPfizer reported $28.4B in revenue for H1 2025, driven by $1.5B in ADC product sales and strong oncology growth. With $13B in BD firepower, Pfizer eyes long-term expansion across key therapeutic areas.
Pfizer's Strategic Bet on BispecificsPfizerPfizer commits up to $6B for rights to SSGJ-707, a PD-1xVEGF bispecific, after in-depth due diligence in China. The asset is expected to complement Pfizer’s ADC portfolio and advance its oncology strategy.
FDA Requests COVID-19 Vaccine Label Updates on Heart RisksModernaThe FDA has requested Pfizer/BioNTech and Moderna update COVID-19 vaccine labels to reflect myocarditis and pericarditis risks in males aged 16-25. This update aligns with new FDA vaccine approval guidelines focusing on high-risk groups.
Pfizer's Talzenna Label Bid Faces SetbackFDAThe FDA’s advisory committee unanimously rejected Pfizer’s proposal to expand Talzenna’s use for prostate cancer patients without HRR mutations, citing insufficient evidence from the TALAPRO-2 trial.
SK Bioscience Wins Key Patent BattleSK BioscienceSK Bioscience wins a key patent dispute against Pfizer in South Korea, enabling global exports of its 13-valent pneumococcal vaccine. The company plans expansion into Southeast Asia and Latin America while advancing next-gen vaccine R&D.
